Vanda Pharmaceuticals (VNDA) Tops Q1 EPS by 1c, Revenues Beat; Offers FY20 Revenue Mid-Point Guidance Above Consensus

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/17/2026

1. SPY
2. FLNC
3. CRM
4. GNRC
5. CRWV
6. NVDA
7. USO
8. LMT
9. TLT
10. AMZN

Go back to Vanda Pharmaceuticals (VNDA) Tops Q1 EPS by 1c, Revenues Beat; Offers FY20 Revenue Mid-Point Guidance Above Consensus

Vanda Pharmaceuticals Reports First Quarter 2020 Financial Results

May 6, 2020 4:01 PM EDT

WASHINGTON, May 6, 2020 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced financial and operational results for the first quarter ended March 31, 2020.

"Our strong financial performance in the first quarter well positions Vanda to continue to innovate and serve our patients, even during this deadly pandemic," said Mihael H. Polymeropoulos, M.D., Vanda's President and CEO.

Key Financial and Corporate Highlights                              

Total revenues from HETLIOZ® and Fanapt® were $58.0 million in the first quarter of 2020, a 22% increase compared to $47.7 million in the first quarter of 2019. HETLIOZ® net product... More